Previous close | 5.80 |
Open | 5.57 |
Bid | 0.05 |
Ask | 10.00 |
Strike | 430.00 |
Expiry date | 2026-01-16 |
Day's range | 5.26 - 5.80 |
Contract range | N/A |
Volume | |
Open interest | 6 |
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
First Quarter Results Show Revenue Decline but Strong Dupixent and Libtayo Sales Growth